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Genetic and biochemical prenatal diagnosis was performed at 11 weeks
of gestation in a family with a proband affected by mut methylmalonic
aciduria (MMA) and homozygotes for the MUT gene c.643G>A
(p.Gly215Ser) mutation. Both chorionic villus and amniotic fluid sam-
ples were used. The presence of high levels of methylmalonic acid and
propionylcarnitine determined by gas chromatography/mass spectro-
metry and LC/MS/MS analysis, respectively, and the identification of
the p.Gly215Ser at a homozygous level in foetal DNA allowed a certain,
rapid and early diagnosis. To our knowledge, this is the first mut MMA
prenatal diagnosis carried out by genetic and biochemical approach.
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Mut methylmalonic aciduria (mut MMA) (MIM
251000), caused by deficiency of the apoenzyme
methylmalonyl-CoA mutase (MCM) (E.C.
5.4.99.2), is an autosomal recessive inborn error
of metabolism. MCM is a mitochondrial enzyme
that requires adenosylcobalamin as a cofactor
and catalyses the isomerization of L-methylmalo-
nyl-CoA to succinyl-CoA.
Mut MMA shows a wide clinical spectrum,
ranging from severe acute neonatal onset with
early death to late onset mild forms.
Biochemical cell studies delineate two phenotypic
variants of MCM deficiency: mut0 with no
detectable enzymatic activity and mut– with resi-
dual mutase activity (1).
To date, about 100 mutations have been
reported in the human MUT gene-encoding
MCM (2–4).
The mature enzyme, a homodimer, has three
functional domains: N-terminal domain involved
in the dimerization of two monomers, (a/b)8 bar-
rel domain with the CoA-binding site and (a/b)5
C-terminal domain with the cobalamin-binding
site (5).
Prenatal diagnosis in MMA has been per-
formed by determination of methylmalonate in
amniotic fluid (AF) and maternal urine, by
measuring the mutase reaction and cobalamin
metabolism in cultured amniocytes, by studies
of [14C]-propionate incorporation and by the
assay of MCM activity in chorionic villi (CV)
(6). Acylcarnitine analysis for MMA prenatal
diagnoses has also been reported (7–9).
Here, we report the first concurrent mol-
ecular and biochemical approach to prenatal
diagnosis at 11 weeks of gestation in a family
with a proband affected by neonatal onset mut
MMA.*The authors contributed to this work equally.
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Materials and methods
Case report
The male proband was born at term after an
uneventful pregnancy and delivery, from healthy
non-consanguineous Italian parents, although
both originate from a small village in Central
Italy. After 3 days, he showed hypotonia,
lethargy, poor feeding, metabolic acidosis
(pH 7.07, PaCO2 15 mmHg, PaO2 136 mmHg,
HCO3
–4.2 mmol/l, base excess (BE) 26.3 mmol/l)
with increased anionic gap (32 mmol/l),
hyperammonemia (1232 mg/dl), hyperlactacidemia,
hyperglycemia, pancytopenia and ketonuria. To
reduce the ammonia level, we started the emergency
treatment with arginine hydrochloride and perito-
neal dialysis. Increased levels of glycine were
detected by plasma amino acids analysis. Urinary
organic acids, analysed by gas chromatography/
mass spectrometry (GC/MS), showed high
levels of methylmalonic acid (1500 mmol/mol
creat, n.v. < 2 mmol/mol creat). These data led to
a diagnosis of MMA. Clinical picture and biochem-
ical findings rapidly improved with high caloric
intake, protein-restricted diet and the administra-
tion of hydroxocobalamin (OHCbl), L-carnitine
and metronidazole.
A very low uptake of [14C]-propionate and no
response to OHCbl in the culture medium were
observed on the proband’s cultured fibroblasts.
Complementation analysis and the lack of
response to OHCbl classified the patient as mut0.
Mutation analysis
Mutation analysis was performed after the par-
ents’ informed consent had been obtained. The
proband’s total RNA was isolated from peripheral
blood with the TRIzol reagent (Life Technologies,
Rockville, MD), and cDNA was generated using
Display THERMO-RT (Eppendorf, Hamburg,
Germany). The proband’s and his parents’ geno-
mic DNA was isolated from whole blood, and
foetal genomic DNA from CV, amniocytes and
foetal skin fibroblasts using QIAamp DNA kit
(Quiagen, Hilden, Germany). Specific primer sets
were designed to amplify MUT cDNA and geno-
mic DNA. The exon 3 polymerase chain reactions
(PCR) product from genomic DNA was obtained
using the primers 50-AGTAAATCATTTTACC-
TTGATTC-30 and 50-CCTACATTCAAGGAA-
CTATAG-30. The amplification conditions
were denaturation at 94 C for 3 min, followed
by 28 cycles (94 C for 30 s, annealing at 53 C
for 30 s, extension at 65 C for 4 min) with a
final extension step at 65 C for 7 min. PCR
products were checked on a 1.5% agarose gel,
excised and purified using the QIAquick gel
extraction kit (Quiagen). Mutation detection
was performed by nucleotide sequencing on
an ABI PRISM 310 genetic analyzer using
BigDye terminator chemicals (Applied
Biosystems, Foster City, CA). Digestion of
amplified PCR products by KpnI restriction
enzyme (Roche Diagnostics, Basel,
Switzerland) was performed according to
manufacturer’s instructions.
Metabolite analysis
Quantification of methylmalonic acid, as tri-
methyl-silyl derivative after solvent extraction
(10), was performed on AF in GC/MS (6890/
5973, Hewlett-Packard, Palo Alto, CA) by stable
isotope dilution with selected ion monitoring
(SIM) (11).
Quantitative assay of acylcarnitine was per-
formed by tandem mass spectrometry (LC/MS/
MS) using an Applied Biosystems-Sciex API 4000
triple-quadrupole mass spectrometer equipped
with a TurboIonSpray source (Applied
Biosystems-Sciex, Toronto, Canada). After metha-
nol extraction, acylcarnitines were analysed as
butyl-esters derivatives as previously reported (12).
Results and Discussion
Sequencing analysis, performed on the proband’s
full-length MUT cDNA, identified a single sus-
pected genetic lesion, c.643G>A. This nucleotide
change will cause a p.Gly215Ser amino acid sub-
stitution. Moreover, the known polymorphisms
c.636A>G (p.Lys212Lys) (13), c.1595A>G
(p.His532Arg) and c.2011G>A (p.Val671Ile)
(14) were detected at cDNA level. The proband’s
genomic DNA sequence analysis of all MUT
exons and intron-exon junctions confirmed the
presence of the c.643G>A (p.Gly215Ser) muta-
tion at a homozygous level in exon 3. This muta-
tion was detected at a heterozygous level in both
parents. The presence of the polymorphisms
c.636A>G (p.Lys212Lys) in exon 3, c.1595A>G
(p.His532Arg) in exon 9 and c.2011G>A
(p.Val671Ile) in exon 12 was also confirmed in
the proband’s genomic DNA. These polymorph-
isms were present in parents’MUT gene and were
inherited at a homozygous level by the proband.
Based on these data, the existence of a common
ancestor can be hypothesized.
The c.643G>A transition removes a natural
KpnI restriction site in the corresponding ampli-
fied PCR product. This was used to further con-
firm the c.643G>A substitution in the proband
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and in both his parents and to screen 100 control
DNAs to exclude the possibility of a benign poly-
morphism. The c.643G>A (p.Gly215Ser) substi-
tution was not detected in any control, suggesting
it is a disease-causing mutation (15).
The p.Gly215Ser mutation has recently been
reported as a homozygous change in another mut
patient. However, clinical data were not described,
and fibroblasts were not available to distinguish
between mut0 and mut– phenotype (2). The identi-
fication of c.643G>A (p.Gly215Ser) mutation at a
homozygous level in our mut0 patient correlates
this mutation with the mut0 phenotype.
To date, 57 missense mutations have been iden-
tified in theMUT gene, and 32 of them occur in the
barrel domain. About 47% of the barrel domain
missense mutations are found in exon 3, suggesting
a basic role of this region in MCM function. From
bacteria to man, the MCM glycine 215 is part
of a highly conserved amino acid stretch
(GTIQNDILKE) (16), and it is also the first resi-
due of the fourth b-strand of the barrel domain
(17). Furthermore, due to the main torsion angle
(f, c), codon 215 can only be occupied by glycine
(2). It can be hypothesized that such amino acid
change leads to an impaired protein folding.
However, the formal proof of causation and
mechanism for this mutation will require further
biochemical investigations, such as overexpression
and kinetic analysis of the mutant enzyme.
As requested by the parents, a prenatal diag-
nosis was performed in their next pregnancy at 11
weeks of gestation. Both CV and AF samples,
collected with family consent, were used to
isolate genomic foetal DNA, and an AF aliquot
was also used for metabolite determinations. The
presence of the p.Gly215Ser amino acid substitu-
tion at a homozygous level, detected by sequen-
cing and enzyme restriction analysis, led us to
diagnose an affected foetus (Fig. 1).
To compare genetic and biochemical data, spe-
cific metabolites were simultaneously determined
by GC/MS and LC/MS/MS on AF.
Quantification of methylmalonic acid, performed
in SIM mode using stable isotope dilution, was
40 mM (n.v. 0–1.9 mM). The level of methylmalonic
acid is in agreement with the values reported in
affected foetuses [6.8–76 mM (9, 18–20, Dr. Divry P,
personal communication)] at 12–20 weeks of
gestation. Quantitative assay of acylcarnitines
showed an increased level of propionylcarnitine
(C3, 9.7 mM, n.v. 0.2–1.6 mM) and an increased
ratio of C3/C0 (0.5, n.v. 0–0.1), C3/C4 (10, n.v.
0.9–2), and C3/C16 (71, n.v. 6.1–22.1). The C3
and C3/C4 values detected in the foetal AF sam-
ple agree with the values reported for affected
foetuses [3.90–11.20 mM and 8.90–15.50 mM,
respectively (9)] at 12–17 weeks of gestation.
The main data of the case are summarized in
Table 1.
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Fig. 1. (a) Partial nucleotide sequence of
exon 3 of MUT gene. The c.643G>A
(p.Gly215Ser) genetic lesion was detected
at a homozygous level in the foetus (I) and
proband(II)andatanheterozygous status
in their parents (III). In panel IV, the
sequence of a control is shown. (b)
Detection of the p.Gly215Ser mutation
by KpnI restriction analysis. The
c.643G>A transition eliminates the KpnI
site of the 478 bp wild-type polymerase
chainreactionsproduct.AfterKpnIdiges-
tion, the wild-type allele gives rise to two
fragments of 326 bp and 152 bp. In the
presenceof themutationataheterozygous
level, three fragments (478 bp, 326 bpand
152 bp)areobtained.Thefigure showsthe
results of the digestion in the foetus, pro-
band, their parents and a normal control.
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Genetic and biochemical data were consistent
with the diagnosis of affected foetus, and the
pregnancy was terminated at 12 weeks of gesta-
tion. After abortion, the p.Gly215Ser mutation
was also confirmed on genomic DNA isolated
from foetal skin fibroblasts.
Most MMA prenatal diagnostic methods,
including methylmalonate and acylcarnitine
determinations, MCM activity and [14C]-propio-
nate incorporation assays are performed in the
mid-trimester of pregnancy (1, 6). Until now,
first-trimester diagnosis of mut MMA had been
performed in only a few cases by measuring
methylmalonate on AF or by measuring mutase
activity and [14C]-propionate incorporation in
CV. This latter assay is poorly reliable (21–23),
because foetal cell cultures are time-consuming
and carries the risk of failure or contamination
from maternal cells (24).
The quantitative assay of acylcarnitines and
methylmalonate is quick and practical. To our
knowledge, at 11 weeks of gestation, no acylcarni-
tine profiles have been previously described for
MMA, while the diagnosis of one affected foetus,
by direct quantification of AF methylmalonate
(26 mM) (21), has been reported. Our results for
methylmalonate and acylcarnitines correlate with
the values detected after 12 weeks of gestation for
affected foetuses. These data suggest that meta-
bolites concentration is significantly high also at
early gestational age as 11 weeks.
Themost accurate method for prenatal diagnosis
in the first trimester is molecular analysis, but the
proband’s mutation(s) must be available, and in
case of heterozygous foetuses, maternal contami-
nation of the DNA samples should be excluded by
marker analysis. To our knowledge, no molecular
prenatal diagnoses have yet been reported for mut
MMA. Ours is the first to use both biochemical
and molecular analysis at 11 weeks of gestation
proving to be adequate and reliable.
In conclusion, we would like to stress that mut
MMA prenatal diagnosis should be performed using
both approaches, together or in a separate manner,
with regard toavailable informationand technologies.
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